American Well Corporation
NYSE:AMWL · New York Stock Exchange
-$0.05 today
Vol 0.02M · Avg 0.08M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-40.6%
avg -44.1%
ROIC
-41.4%
avg -42.5%
ROA
-29.6%
avg -33.8%
Analysis
ROA is currently the strongest return metric at -29.6% versus its period average of -33.8%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Ido Schoenberg | Chairman & Chief Executive Officer | $2.87M | — | 61 | $114,920.00 | 0.69% |
Roy Schoenberg | Executive Vice Chairman | $2.68M | — | 57 | $114,920.00 | 0.69% |
Mark J. Hirschhorn | Executive Vice President, Chief Operating Officer & Chief Financial Officer | $2.58M | — | 61 | $253,999.00 | 1.52% |
Dan Zamansky | Chief Product & Technology Officer | $1.01M | — | 42 | $241,080.00 | 1.44% |
Phyllis I. Gotlib | President of Amwell International | $931,547.00 | — | 68 | $163,004.00 | 0.98% |
Paul Francis McNeice | Vice President of Accounting | — | — | 49 | $10,616.00 | 0.06% |
Cynthia Horner FAAFP | Chief Medical Officer & President of Amwell Medical Group | — | — | — | — | — |
Anna Nesterova | Head of Legal | — | — | — | — | — |
Michael Miller | Senior Vice President & Chief Sales Officer | — | — | — | — | — |
Sue Dooley | Head of Investor Relations | — | — | — | — | — |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
1
$4,937.90
Sells
24
$585,848.32
Net Sentiment
$580,910.42
Net selling
Most Active
Gotlib Phyllis
7 transactions
1–10 of 25
Analysis
Insiders reported 1 buys worth $4,937.90 and 24 sells worth $585,848.32 over the last 12 months. That adds up to net selling of $580,910.42. Gotlib Phyllis was the most active insider with 7 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +23.0% | -2.2% (8yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +23.0% over three years. Forward estimates point to Revenue at -2.2% (8yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
ALX Oncology Holdings Inc.
NASDAQ:ALXO
$212.61M
Immunic, Inc.
NASDAQ:IMUX
$136.78M
Repare Therapeutics Inc.
RPTX
$114.24M
Adverum Biotechnologies, Inc.
ADVM
$96.26M
CAMP4 Therapeutics Corporation
NASDAQ:CAMP
$89.00M
Precision BioSciences, Inc.
NASDAQ:DTIL
$78.25M
Biomea Fusion, Inc.
NASDAQ:BMEA
$69.61M
Fractyl Health, Inc. Common Stock
NASDAQ:GUTS
$61.36M
aTyr Pharma, Inc.
ATYR
$43.18M
EUDA Health Holdings Limited
EUDA
$28.39M
Who manages AMWL?
American Well Corporation (AMWL) lists 10 active executives. The top listed executive is Paul Francis McNeice, Vice President of Accounting.
Are AMWL insiders buying or selling?
Recent insider activity shows net selling of $7.88M.
Explore More
Continue the stock analysis
Jump to another research area for this company.